Neurology & Psychiatry · 1965
Methadone maintenance treatment for heroin addiction (Dole and Nyswander)
Heroin addiction in the 1960s was treated almost entirely through detoxification and abstinence programs, most of which had relapse rates that commonly exceeded 90 percent within a year of discharge. Pharmacologic maintenance was not part of the therapeutic vocabulary. Vincent Dole, an internist at Rockefeller University who had spent his career studying metabolic diseases, began collaborating with Marie Nyswander, a psychiatrist with extensive experience treating heroin-addicted patients in Harlem, in 1963. Their hypothesis was that chronic heroin use produced a persistent metabolic alteration that abstinence alone could not reverse.
They started with two inpatients in early 1964, testing morphine and then switching to methadone after finding that its longer duration of action produced stable plasma levels without the oscillating highs and cravings associated with shorter-acting opioids. By 1965, when they published in JAMA, the trial had grown to 22 patients. Criminal activity among the participants dropped substantially, and 16 of the 22 held employment or attended school during treatment, outcomes that abstinence-based programs had rarely produced.
The framing Dole and Nyswander chose was as deliberate as the clinical design. They described heroin addiction explicitly as a metabolic disease, not a character defect, and drew the analogy to insulin in diabetes: methadone corrected an underlying dysfunction rather than substituting one addiction for another. That framing was controversial. Abstinence advocates and some law enforcement officials argued that maintenance simply sustained dependence, and moral objections to prescribing opioids to addicts ran deep in both medicine and policy.
Federal support came gradually. The FDA approved methadone for maintenance treatment in 1972, and the number of patients in licensed programs expanded through the 1970s and 1980s, eventually reaching several hundred thousand in the United States by the 1990s. Randomized trials conducted after the initial Dole-Nyswander series confirmed that higher methadone doses were associated with better retention and greater reduction in illicit opioid use.
Buprenorphine, a partial opioid agonist approved for office-based maintenance treatment in 2002, extended the Dole-Nyswander model beyond federally licensed clinics and made treatment accessible to primary care physicians. Methadone retained a role for patients with more severe dependence or prior treatment failure. The opioid epidemic of the 2010s substantially increased demand for both agents and renewed policy attention to the access barriers that had limited uptake since the original 1965 publication.
Key People
- Vincent Dole — Internist who designed the methadone maintenance protocol at Rockefeller
- Marie Nyswander — Psychiatrist who co-developed and co-published the treatment approach
- Mary Jeanne Kreek — Rockefeller pharmacologist who extended methadone research over subsequent decades
JAMA, 1965
Related landmarks
- 1967 · L-DOPA for Parkinson disease (Cotzias) (Neurology & Psychiatry)
- 1958 · Imipramine, the first tricyclic antidepressant (Kuhn) (Neurology & Psychiatry)
- 1952 · Chlorpromazine in psychosis (Delay & Deniker) (Neurology & Psychiatry)
- 1949 · Cade's lithium for mania (Neurology & Psychiatry)